Register Log-in Investor Type

Healthcare News

This sector includes biotechnology, pharmaceuticals, research services, home healthcare, hospitals, long-term care facilities, and medical equipment and supplies. Companies in this sector include Astra Zeneca, Pfizer and Roche Holding.

23 Sep 2021

BB Biotech discloses a third bargain top up this quarter

BB Biotech has disclosed an increase in its holding in Mersana Therapeutics (Nasdaq:NRSN), the timing of which suggests it again aims to capitalise on a 40% fall in an investee company’s share price that occurred after a clinical trial update earlier in the month. The Swiss investment company disclosed the increased holding in a SEC […]

10 Sep 2021

QuotedData’s morning briefing 10 September 2021

In QuotedData’s morning briefing 10 September 2021: RTW Venture (RTW) has announced a new portfolio investment in Lycia Therapeutics, following its participation in the company’s US$70m series B financing round, the proceeds of which are intended to advance Lycia’s discovery pipeline of LYTAC degraders. Lycia is a privately held biotechnology company developing extracellular protein degradation […]

10 Aug 2021

Stellar Moderna share drives BB Biotech back to near all time high

Swiss investor BB Biotech’s (SWX:BION) large position in US covid vaccine producer Moderna continues to drive a remarkable performance in a volatile US biotech market. Yesterday, Moderna (Nasdaq: MRNA) surged 17% to a new all-time high of $484.5/share, giving it a market capitalisation of $167bn. Moderna is the largest of BB Biotech’s holdings accounting for […]

23 Jul 2021

Moderna drives strong performance at BB Biotech

BB Biotech’s (SWX:BION) large position in US covid vaccine producer Moderna drove a strong performance against a volatile US biotech market in the first half of this year. Moderna was the second best performer within BB Biotech’s portfolio during the period, with a rise of 105%, beaten only by Essa Pharmaceuticals, whose stock was up […]

05 Jul 2021

QD view – Volatility remains hallmark of biotech in first half

Essa Pharmaceutials (Nasdaq: EPIX) and Moderna (MRNA) may have been the top performers within Swiss investment company BB Biotech’s (SIX:BION) 34-strong portfolio in the first half, sporting stock price rises of 137% and 124% respectively, but these gains are modest by comparison with some of the ones from within the wider world of biotech investing. […]

01 Jul 2021

BB Biotech ends volatile Q2 on a (near) all-time high

BB Biotech (SWX:BION) ended the first half with its shares up 22.2% and at CHF87 at the close yesterday, just 5% below their all-time high of CHF90 that was reached in February. The Swiss investment company’s net asset value grew by 8.9% in the first half to CHF73.1 per share, which seems to be a […]

15 Jun 2021

RTW backs Umoja Biopharma

RTW backs Umoja Biopharma – Umoja Biopharma, Inc. has just completed a $210m Series B financing round. RTW Venture Fund participated in the financing round together with other investment firms, including other investment vehicles of RTW Investments, LP. Umoja is a US-based privately held oncology company. It is using a new approach to immunotherapy, reprogramming immune cells directly […]

15 Jun 2021

BB Biotech ups stake in high conviction stocks

BB Biotech (SWX:BION) increased its stake in the US cancer biotech MacroGenics by a fifth just over a week ago, seemingly taking advantage of a fall in the company’s share price in the wake of the ASCO scientific meeting earlier this month. Hitherto, MacroGenics ranked in tenth position in BB Biotech’s portfolio, accounting for 3.6% […]

08 Jun 2021

BB Biotech’s Biogen bet plays out successfully

BB Biotech’s large bet on the US regulatory approval of Biogen’s Alzheimer’s disease therapy aducanumab has met with success, after the FDA rendered an approval in a landmark, although highly controversial, decision yesterday. The news prompted a huge rise in Biogen’s share price (Nasdaq: BIIB), which closed 38% up at $395/share, having peaked at $450 […]

07 Jun 2021

BB Biotech positions move on first day of ASCO

Two of BB Biotech’s holdings were among the largest movers – one up and one down – on Friday, the first day of ASCO – the American Society of Clinical Oncology – when stocks responded to an avalanche of updated clinical trial data released at the start of the virtual scientific meeting. Fate Therapeutics, BB […]

21 May 2021

BB Biotech portfolio positions hit on ASCO disclosures

A 2020 vintage investment for Switzerland’s BB Biotech has turned out to be one of the highest profile victims of the stock price moves occasioned by the ASCO abstract release earlier this week. Black Diamond Therapeutics (Nasdaq: BDTX) saw its shares fall by 37% yesterday after early-stage results of its lead compound BDTX-189 – although […]

07 May 2021

QuotedData’s morning briefing 7 May 2021

In QuotedData’s morning briefing 7 May 2021: Shareholders have approved both a change of name and a revised investment Policy for Jupiter US Smaller Companies (JUS), which reflects the change of investment manager to US based Brown Advisory (click here to read our initiation note on the company which takes a detailed look at Brown’s […]

06 May 2021

BB Biotech top holding hit by US Covid vaccine IP move

Shares in the US Covid vaccine developer Moderna – the second largest holding for giant Swiss investment company BB Biotech – fell by 6% yesterday, after the Biden Administration said it would support an exceptional waiver of IP protection on COVID-19 vaccines for developing countries through the World Trade Organisation. Moderna accounted for 7.8% of […]

23 Apr 2021

BB Biotech discloses portfolio changes in Q1

Swiss investor BB Biotech made two new investments in the first quarter in US small caps – Essa Pharma and Revolution Medicines – while exiting its positions in Cidara Therapeutics and Voyager Therapeutics, according to its portfolio update published earlier today. Essa Pharma (Nasdaq: EPIX) is developing a small molecule drug, EPI-7386, in metastatic castration-resistant […]

16 Apr 2021

Schroder British Opportunities invests in Cera Care

Schroder British Opportunities (SBO) has announced an investment into Cera Care Limited, as part of a new funding round to support the company’s growth plans, in a transaction led by Evolve HealthCare Partners, a pan-European healthcare focused private equity firm. Cera is a technology-enabled home care provider founded and based in the UK. The new […]

01 Apr 2021

BB Biotech ends a turbulent first quarter in good health

BB Biotech ends a turbulent first quarter in good health BB Biotech posted a respectable performance in the first quarter of 2021, in a period that proved to be quite turbulent for biotech stocks. As of 31 March, BB Biotech stock closed at CHF82.20, up 15.4% year to date, while the NAV was CHF70.75/share, up […]

30 Mar 2021

RTW backs Pyxis Oncology

RTW backs Pyxis Oncology – RTW Venture Fund Limited has highlighted an announcement by Pyxis Oncology, Inc. On 30 March 2021 that company completed a $152 million Series B financing round, which was co-led by RTW Investments, LP. The company, alongside other investment vehicles of the Investment Manager, confirms that it participated in the financing round together with […]

23 Mar 2021

BB Biotech top pick Ionis hit by safety setback

BB Biotech top pick Ionis hit by safety setback – BB Biotech’s top holding, US antisense therapeutics pioneer Ionis Pharmaceuticals, has suffered a material setback, after the independent committee monitoring trials of one of its lead development products – tominersen, which is partnered with the pharma giant Roche – recommended discontinuation of dosing in Phase III […]

16 Mar 2021

Biopharma Credit looking healthy

Biopharma Credit looking healthy – BioPharma Credit has published its annual report for the period ended 31 December 2020. Highlights are: NAV was fairly flat during the period, decreasing by $0.018 from $1.0217 to $1.0037 8.29 cents per share in total dividends during period, comfortably ahead of the target to distribute at least 7 cents per […]

11 Feb 2021

Syncona backs Quell financing

Syncona backs Quell financing – Syncona Ltd  has made a new £25.3m commitment to a £61.0m expanded Series A financing for Quell Therapeutics. This is the largest amount of funding to date for any stand-alone engineered T regulatory cell (Treg) company [see below] and takes Syncona’s total commitment to this business to £59.3m (of which £35.1m […]

05 Feb 2021

Syncona’s Achilles Therapeutics announces positive trial recommendation

Achilles Therapeutics, a Syncona portfolio company, has announced that an Independent Data and Safety Monitoring Committee (IDSMC) has completed its first review of the ongoing, first-in-human Phase I/II CHIRON and THETIS trials and has recommended that both clinical trials continue as planned. Achilles Therapeutics is a clinical-stage biopharmaceutical company developing precision T cell therapies to […]

05 Feb 2021

Successful IPO for RTW Venture Fund’s Landos Biopharma

RTW Venture Fund has provided a brief update on portfolio company Landos Biopharma’s IPO. The IPO raised US$100 million by offering 6,250,000 shares at $16.00 per share, and Landos is now listed on the Nasdaq Global Market under ticker: LABP. Landos was one of the seed assets included in the Company’s portfolio at the time of […]

29 Jan 2021

FDA delay backs BB Biotech view on Biogen Alzheimer’s drug

US biotech giant Biogen – in which the Swiss investor BB Biotech (SIX:BION) holds a stake equivalent to 2.9% of its portfolio value – has seen its stock open up 7% this morning on the back of announcement by the FDA of a three-month delay in the review of the controversial Alzheimer’s therapy aducanumab. The […]

25 Jan 2021

BB Biotech bets big on an unexpected Alzheimer’s approval

Switzerland’s BB Biotech (SIX:BION) has made a $130m investment in Biogen, a US large cap biotech company that would normally fall outside its small-to mid cap investment area, in a bid to capitalise on the possible approval over the next few weeks of an Alzheimer’s therapy that has been largely written off by the market. […]

22 Jan 2021

BB Biotech raises dividend after strong year

Switzerland’s BB Biotech (SIX:BION) recorded a solid investment performance in 2020 despite the volatile markets, according to its preliminary report. The trust saw a 16.4% rise in NAV (with a 12 % rise in share price) over the year, with a 20.6% gain in portfolio value (25.5% in US dollars) and the share price up […]

07 Jan 2021

RTW makes new investment in Biomea Fusion

RTW makes new investment in Biomea Fusion – RTW Venture Fund, alongside other investment vehicles of RTW Investments, LP – its investment manager – and other investment firms, has participated in a $56m Series A financing round for Biomea Fusion. Biomea is a US-based privately held precision oncology company dedicated to developing innovative medicines targeting specific […]

10 Dec 2020

RTW’s Rocket takes off on good clinical data

RTW’s Rocket takes off on good clinical data – RTW Venture Fund notes positive data updates on four clinical trials of Rocket Pharmaceuticals, Inc. (NASDAQ: RCKT). This is the largest holding in RTW’s portfolio, representing about 30% of NAV. Rocket is advancing an integrated and sustainable pipeline of first-in-class genetic therapies that correct the root cause […]

30 Nov 2020

New IPO – Intuitive Investments

New IPO – Intuitive Investments – Intuitive Investments Group, a closed-end investment company focussed on the life sciences sector, announces its intention to seek admission of the entire issued and to be issued ordinary share capital of the company to the AIM market of the London Stock Exchange, and a conditional placing of 37,500,000 new ordinary […]

19 Nov 2020

Syncona founds Purespring

Syncona founds Purespring Therapeutics with a £45.0 million Series A financing commitment. Syncona will have an 84% stake in the business. Purespring Therapeutics is one of the first AAV gene therapy companies focused on the kidney. It has been founded around the work of Professor Moin Saleem, Professor of Paediatric Renal Medicine at the University of Bristol, […]

02 Oct 2020

Successful IPO for RTW Venture Fund’s Pulmonx Corporation

RTW Venture Fund’s portfolio company, Pulmonx Corporation, announced on 30 September 2020 the pricing of its US$190 million initial public offering (IPO) as well as its admission to trading on Nasdaq Global Market under the ticker: LUNG. Pulmonx is a medical device company that commercializes the Zephyr Valve System, which it says is the first […]

Please review our cookie, privacy & data protection and terms and conditions policies and, if you accept, please select your place of residence and whether you are a private or professional investor.

You live in…

You are a…